Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA covers the month of November 2016. The report addresses legal and regulatory matters subsequent to the quarterly report for the nine months ended September 30, 2016.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on a legal settlement update rather than financial performance data.
Material Changes
The primary material change is an extension of the opt-in process schedule for a settlement agreement regarding wrongful death and personal injury claims against Fresenius Medical Care Holdings, Inc. (FMCH) and affiliates. These claims relate to the acid concentrate products NaturaLyte and GranuFlo. The financial terms of the agreement in principle remain unchanged.
Guidance, Outlook, and Risks
Settlement Timeline:
- Plaintiffs must advise FMCH of acceptance by November 14, 2016.
- The Company has until December 2, 2016, to exercise rights to void the settlement.
- Payment must be made by December 9, 2016, if the settlement is confirmed.
- Continued litigation risk regarding NaturaLyte and GranuFlo products until the settlement is finalized.
- Potential financial outflow contingent on the confirmation of the settlement agreement.
Investor Verification Checklist
- Verify the final confirmation status of the NaturaLyte and GranuFlo settlement by December 9, 2016.
- Confirm the total financial liability associated with the settlement, as specific amounts are not detailed in this filing.
- Review the prior October 2016 Form 6-K for the original agreement terms and initial financial estimates.
- Monitor for any future filings regarding the Company's decision to void the settlement before the December 2, 2016 deadline.